Beneficial effect of vardenafil on aortic stiffness and wave reflections

Journal of Clinical Pharmacology

Volumn 52, Issue 8, 2012, Pages 1215-1221

  Vlachopoulos, Charalambos ^a   Terentes Printzios, Dimitrios ^a   Ioakeimidis, Nikolaos ^a   Rokkas, Konstantinos ^a   Samentzas, Alexios ^a   Aggelis, Athanasios ^a   Kardara, Despina ^a   Stefanadis, Christodoulos ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

augmentation index; cardiovascular risk; erectile dysfunction; Pulse wave velocity; vardenafil

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; VARDENAFIL;

ADULT; AGED; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD VESSEL PARAMETERS; CAROTID ARTERY PULSE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; ERECTILE DYSFUNCTION; FEMORAL ARTERY; FLUSHING; HEART RATE; HUMAN; MALE; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WAVE REFLECTION;

AORTA; ARTERIAL PRESSURE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HEART RATE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PIPERAZINES; PULSE WAVE ANALYSIS; SULFONES; TRIAZINES; VASCULAR STIFFNESS;

EID: 84864411078     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011413586     Document Type: Article

References (41)

1. Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2007 ; 8: 965-974 (Pubitemid 351227484)
2. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med. 2009 ; 6: 658-674
3. Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Rokkas K, Stefanadis C. PDE5 inhibitors in non-urological conditions. Curr Pharm Des. 2009 ; 15: 3521-3539
4. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005 ; 96: 313-321 (Pubitemid 40978596)
5. Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract. 2010 ; 64: 848-857
6. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol. 2007 ; 52: 1590-1600 (Pubitemid 350052419)
7. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J. 2006 ; 27: 2640-2648 (Pubitemid 44729862)
8. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Stefanadis C. The triad: erectile dysfunction-endothelial dysfunction-cardiovascular disease. Curr Pharm Des. 2008 ; 14: 3700-3714
9. Vlachopoulos C, Rokkas K, Ioakeimidis N, et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol. 2005 ; 48: 996-1002 (Pubitemid 41641653)
10. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 ; 55: 1318-1327
11. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010 ; 31: 1865-1871
12. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 ; 27: 2588-2605 (Pubitemid 44627304)
13. Vlachopoulos C, Alexopoulos N, Stefanadis C. Aortic stiffness: prime time for integration into clinical practice?. Hellenic J Cardiol. 2010 ; 51: 385-390
14. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007 ; 50: 154-160 (Pubitemid 46986036)
15. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010 ; 7: 524-540
16. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation. 2010 ; 122: 88-95
17. Kukreja R, Salloum F, Xi L. Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart. Int J Impot Res. 2007 ; 19: 226-227 (Pubitemid 46340844)
18. Szabó G, Radovits T, Veres G, et al. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg. 2009 ; 36: 657-664
19. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther. 2006 ; 316: 654-661 (Pubitemid 43130992)
20. Korkmaz S, Radovits T, Barnucz E, et al. Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta. Eur J Pharmacol. 2009 ; 615: 155-162
21. Hirschberg K, Radovits T, Loganathan S, et al. Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy. J Thorac Cardiovasc Surg. 2009 ; 137: 1508-1514
22. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi SI. Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clin Exp Med.:
23. Jackson G, Montorsi P, Adams MA, et al. Cardiovascular aspects of sexual medicine. J Sex Med. 2010 ; 7: 1608-1626
24. Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res. 2006 ; 18: 464-469 (Pubitemid 44330297)
25. Mazo EB, Gamidov SI, Iremashvili VV. Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernosal arteries? A pilot study. BJU Int. 2006 ; 98: 1054-1058 (Pubitemid 44536458)
26. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003 ; 348: 593-600 (Pubitemid 36204953)
27. Foresta C, Lana A, Cabrelle A, et al. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int J Impot Res. 2005 ; 17: 377-380 (Pubitemid 41025774)
28. Foresta C, Caretta N, Lana A, et al. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol. 2007 ; 51: 1411-1417
29. Corona G, Monami M, Boddi V, et al. Pulse pressure independently predicts major cardiovascular events in younger but not in older subjects with erectile dysfunction. J Sex Med. 2011 ; 8: 247-254
30. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Arterial function and intima-media thickness in hypertensive patients with erectile dysfunction. J Hypertens. 2008 ; 26: 1829-1836
31. Vlachopoulos C, Hirata K, O'Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med. 2003 ; 8: 243-248 (Pubitemid 38585138)
32. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005 ; 96: 1436-1440 (Pubitemid 41566628)
33. Schofield RS, Edwards DG, Schuler BT, et al. Vascular effects of sildenafil in hypertensive cardiac transplant recipients. Am J Hypertens. 2003 ; 16: 874-877 (Pubitemid 37204687)
34. Mahmud A, Hennessy M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens. 2001 ; 15: 707-713 (Pubitemid 32975870)
35. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006 ; 48: 622-627 (Pubitemid 44843865)
36. Eardley I, Lee JC, Shabsigh R, et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med. 2010 ; 7: 244-255
37. Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol. 2004 ; 498: 189-194 (Pubitemid 39208078)
38. Herrmann HC, Levine LA, Macaluso J, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006 ; 3: 303-308
39. Bank AJ, Kelly AS, Kaiser DR, et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med. 2006 ; 11: 251-257 (Pubitemid 46470504)
40. Dadkhah F, Safarinejad MR, Asgari MA, Hosseini SY, Lashay A, Amini E. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res. 2010 ; 22: 51-60
41. Vlachopoulos C, Aznaouridis K, Dagre A, et al. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. Eur Heart J. 2007 ; 28: 2102-9 (Pubitemid 47517441)